N-{3-[(diphenylacetyl)amino]propyl}-4-oxo-3,4-dihydro-2-quinazolinecarboxamide

Product NameN-{3-[(diphenylacetyl)amino]propyl}-4-oxo-3,4-dihydro-2-quinazolinecarboxamide
CAS1119503-63-7
MFC26H24N4O3
MW440.49
EINECS
MOL File1119503-63-7.mol

Chemical Properties

Density	1.26±0.1 g/cm3(Predicted)
storage temp.	Store at -20°C
form	Solid
pka	10.06±0.20(Predicted)
color	White to off-white

Usage And Synthesis

Uses

Biological Activity

JNc-440 is a potent antihypertensive agent. JNc-440 can enhance the interaction of TRPV4 and Ca2+-activated potassium channel 3 (KCa2.3) in endothelial cells. JNc-440 can also enhance vasodilation, and exerted antihypertensive effects in mice[1]. JNc-440 (1 mg/kg; IV; single dosage) improves endothelium-dependent relaxation in small resistance arteries and to lower blood pressure[1].

in vivo

JNc-440 (1 mg/kg; IV; single dosage) improves endothelium-dependent relaxation in small resistance arteries and to lower blood pressure^[1].

Animal Model:	TRPV4^-/- and wild‐type C57BL/6J mice (hypertensive induced by NOS inhibitor Nω-nitro-L-arginine, AngII and high-salt diet)^[1]
Dosage:	1 mg/kg
Administration:	IV; single dosage
Result:	Increased the impaired TRPV4‐KCa2.3 interaction to improve endothelium‐dependent relaxation in small resistance arteries and to lower blood pressure.

References

[1]. He D, et al. Treatment of hypertension by increasing impaired endothelial TRPV4-KCa2.3 interaction. EMBO Mol Med. 2017 Nov;9(11):1491-1503.